Suzhou Medical College Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3

Organization Overview

First Clinical Trial
2018
NCT04816123
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

First Affiliated Hospital of Suzhou Medical College

Active Ingredients

Drugs in Phase 3 Trials (2)

imatinib (gleevec) (1 trial)

Olverembatinib (1 trial)

Drugs in Phase 2 Trials (1)

niraparib (zejula) (1 trial)

Drugs in Phase 1 Trials (5)

Chiauranib (1 trial)

chiglitazar (Bilessglu) (2 trials)

donafenib (Zepsun) (1 trial)

omarigliptin (1 trial)

xzp-3621 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Ovarian Epithelial (Phase 2)

Diabetes Mellitus, Type 2 (Phase 1)

Ovarian Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 8